Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOL101 for Prophylaxis of Acute Organ Rejection in Renal Transplantation
NCT01154387Phase 2Unknown
- Sponsor
- Tolera Therapeutics, Inc.
- Start
- Jul 2010
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TOL101 in kidney transplant rejection, sponsored by Tolera Therapeutics, Inc.. Status: unknown.
02
Drugs
TOL101
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01154387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154387.